Adaptimmune Therapeutics (ADAP) Tops Q3 EPS by 2c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.32 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results
• 374Water Inc (SCWO) Misses Q2 EPS by 15c